Keratoacanthoma

Common Name(s)

Keratoacanthoma, Muir-Torre Syndrome

Muir-Torre syndrome is an autosomal dominant skin condition of genetic origin, characterized by tumors of the sebaceous gland or keratoacanthoma that are associated with visceral malignant diseases (cancers of the internal organs). The cutaneous characteristics of Muir-Torre syndrome are sebaceous adenoma, sebaceous epithelioma, sebaceous carcinoma, or multiple keratoacanthomas, whereas visceral malignant diseases include colorectal, endometrial, urological, and upper gastrointestinal tumors. Men are affected twice as often as women. Muir-Torre syndrome is associated with hereditary non-polyposis colon cancer (HNPCC), an autosomal dominant cancer genetic syndrome. Sebaceous neoplasms associated with Muir-Torre syndrome exhibit microsatellite instability (MSI), as do other HNPCC-related cancers.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Keratoacanthoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Keratoacanthoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Keratoacanthoma" returned 77 free, full-text research articles on human participants. First 3 results:

Clinicopathological characteristics of xeroderma pigmentosum associated with keratoacanthoma in an infant.
 

Author(s): Xu'e Han, Hongbiao Jing, Cuijie Liu, Jinfeng Zheng

Journal: J Cancer Res Ther. ;11(3):665.

 

A rare case of xeroderma pigmentosum coexisted with keratoacanthoma in an 18-month-old boy was reported. The boy was admitted with unequal size, irregularly shaped brown spots, patches and depigmentation spots on his face. A well-circumscribed hemispherical mass measuring 3 cm×3 ...

Last Updated: 13 Oct 2015

Go To URL
CD1A-positive cells and HSP60 (HSPD1) levels in keratoacanthoma and squamous cell carcinoma.
 

Author(s): Daniela Cabibi, Everly Conway de Macario, Sabrina Ingrao, Rossana Porcasi, Francesco Zucco, Alberto J L Macario, Francesco Cappello, Francesca Rappa

Journal: Cell Stress Chaperones. 2016 Jan;21(1):131-7.

 

CD1a is involved in presentation to the immune system of lipid antigen derived from tumor cells with subsequent T cell activation. Hsp60 is a molecular chaperone implicated in carcinogenesis by, for instance, modulating the immune reaction against the tumor. We have previously postulated ...

Last Updated: 16 Dec 2015

Go To URL
Keratoacanthoma of the Lip: Activation of the mTOR Pathway, Tumor Suppressor Proteins, and Tumor Senescence.
 

Author(s): Caroline Siviero Dillenburg, Manoela Domingues Martins, Luise Meurer, Rogerio Moraes Castilho, Cristiane Helena Squarize

Journal: Medicine (Baltimore). 2015 Sep;94(38):e1552.

 

The PI3K-PTEN-mTOR is one of the most important pathways involved in cancer development and progression; however, its role in keratoacanthoma (KA) is poorly understood. In this study, we investigated the activation of key proteins in the PI3K-mTOR pathway in lip KA. We analyzed the ...

Last Updated: 25 Sep 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Keratoacanthoma" returned 4 free, full-text review articles on human participants. First 3 results:

[Role of the pathologist in the diagnosis of palpebral keratoacanthoma: case report and literature review].
 

Author(s): A Harmouch, M C Chefchaouni, M Maher, S Sefiani

Journal: J Fr Ophtalmol. 2012 Dec;35(10):816.e1-3.

 

We report the case of a keratoacanthoma of the lower lid in a 14-year-old girl posing diagnostic difficulty with differentiating the lesion from a verrucous squamous cell carcinoma on histologic examination of an incisional biopsy. It was only upon complete excision of the tumor that ...

Last Updated: 11 Dec 2012

Go To URL
Keratoacanthoma of the inferior lip: review and report of case with spontaneous regression.
 

Author(s): Lara Maria A Ramos, Sérgio V Cardoso, Adriano M Loyola, Marcus A Rocha, Antônio Francisco Durighetto-Júnior

Journal: J Appl Oral Sci. ;17(3):262-5.

 

Keratoacanthoma (KA) is a self-limited benign epithelial proliferative lesion that eventually presents with very similar clinical features to squamous cell carcinoma. Many KA appear in the vermilion border of the lips and therefore dental professionals must be familiar of the disease. ...

Last Updated: 25 May 2009

Go To URL
Conjunctival keratoacanthoma.
 

Author(s): S A Schellini, M E Marques, M F Milanezi, C E Bacchi

Journal: Acta Ophthalmol Scand. 1997 Jun;75(3):335-7.

 

Keratoacanthoma is a rapidly growing skin neoplasia that may stabilize or regress spontaneously. We describe here a case of conjunctival keratoacanthoma and comment about the clinical signs and symptoms and pathological findings.

Last Updated: 19 Sep 1997

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
 

Status: Not yet recruiting

Condition Summary: Adenoid Cystic Carcinoma; Adnexal Carcinoma; Apocrine Carcinoma; Eccrine Porocarcinoma; Extraocular Cutaneous Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Non-Melanomatous Lesion; Paget Disease; Papillary Adenocarcinoma; Primary Cutaneous Mucinous Carcinoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Spiradenocarcinoma; Squamous Cell Carcinoma of Unknown Primary Origin; Stage III Skin Cancer; Stage IV Skin Cancer; Sweat Gland Carcinoma; Trichilemmocarcinoma; Vulvar Squamous Cell Carcinoma

 

Last Updated: 8 Dec 2016

Go to URL